TWiV 910: COVID-19 clinical update #119 with Dr. Daniel Griffin
b'
In COVID-19 clinical update #119, Dr. Griffin reviews tixagevimab for infection prevention, ivermectin for outpatient infection treatment, symptom rebound after PAXLOVID treatment, bamlanivimab minimally impacting immune response to vaccination, in-hospital mortality among infection patients, residual viral antigen in patients following infection, usage of Casirvimab/Imdevimab and Remdesivir in infected patients with depleted B-cells, and rheumatic symptoms following infection.
Subscribe (free):\\xa0Apple Podcasts,\\xa0Google Podcasts,\\xa0RSS,\\xa0email
Become a\\xa0patron\\xa0of\\xa0TWiV!
Links for this episode
- Tixagevimab-Cilgavimab\\xa0for infection prevention (NEJM)
- Ivermectin\\xa0for outpatient infection treatment (medRxiv)
- Symptom rebound after\\xa0PAXLOVID treatment\\xa0(IDSA)
- Bamlanivimab minimally impacts\\xa0immune response to vaccination (Sci Transl Med)
- In-hospital\\xa0morality among infected\\xa0patients (IDSA)
- Casirvimab/Imdevimab & Remdesivir\\xa0for infected B-cell depleted patients (IDSA)
- PAXLOVID patient eligibility\\xa0screening checklist (FDA)
- Remdesivir fact sheet\\xa0for providers (Veklury)\\xa0
- Bebtelovimab fact sheet\\xa0for providers (FDA)
- Residual viral antigen in\\xa0patients post infection\\xa0(IDSA)
- Rheumatic symptoms\\xa0following infection (IDSA)
- Contribute to\\xa0FIMRC fundraiser at PWB
- Dr. Griffin\\u2019s treatment guide (pdf)
- Letters read\\xa0on TWiV 910
- Timestamps by Jolene. Thanks!
Intro music is by\\xa0Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv